News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Rainbow BioSciences, LLC Negotiates Funding Terms with n3D
February 6, 2012
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
NOKOMIS, Fla.--(BUSINESS WIRE)--Rainbow Biosciences, the biotech division of Rainbow Coral Corp. (OTCBB:RBCC), announced today that it’s on the cusp of a major breakthrough in its business relationship with n3D Biosciences.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
MORE ON THIS TOPIC
Layoffs
TScan cuts 75% of workforce while shifting focus to solid tumor program
September 3, 2026
·
2 min read
·
Angela Gabriel
Funding
US to grant up to $125M for personalized RNA manufacturing innovation
September 3, 2026
·
2 min read
·
Michael Gibney
Deals
GSK inks another Asia alliance, betting up to $1.3B for HUTCHMED’s cancer therapy
September 3, 2026
·
1 min read
·
Tristan Manalac
FDA
Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals
September 2, 2026
·
2 min read
·
Jef Akst
